MAR001 reduces triglycerides without worsening glycemic control in Phase 2b trial
FROM THE WIRE · GLOBENEWSWIRE.COM
Part A of TYDAL-TIMI 78 Trial met all objectives, with statistically significant placebo-adjusted triglyceride reductions of 39.1%–45.5% across all three doses at Week 12 and up to 57.2% in participants with baseline triglycerides ≥300 mg/dL
Read at the source ↗MARKET IMPACTNEUTRAL✦ News Impact agent estimateTone: expected bullishPositive clinical data published in NEJM can matter for the developer, a Lisata subsidiary.AI-generated summary
✦ IN BRIEF · AIAI-generated summary
- 01Part A of the TYDAL-TIMI 78 trial met all objectives.
- 02Placebo-adjusted triglyceride reductions were 39.1%-45.5% at Week 12.
- 03Results were published in The New England Journal of Medicine.
NEWS IMPACT AND MARKET REACTIONChange since the story · reference
Impact and summary are estimates by the News Impact AI agent, not financial advice.Open in Markets